Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCR-MYC in refractory solid tumors, multiple myeloma, or lymphoma
NCT02110563Phase 1Terminated
- Sponsor
- Novo Nordisk
- Start
- Apr 2014
- Primary completion
- Oct 2016
- Modality
- Antisense DNA, Lipid-based Nanoparticles, Conjugated siRNA
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DCR-MYC in solid tumor, multiple myeloma (MM), non-Hodgkin lymphoma (NHL) and 1 more, sponsored by Novo Nordisk. Primary endpoint: Number of patients with adverse events as a measure of safety and tolerability. Started Apr 2014; status: terminated.
02
Drugs
DCR-MYC
03
Conditions
solid tumormultiple myeloma (MM)non-Hodgkin lymphoma (NHL)Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02110563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02110563.